ditert-butyl(cyclopenta-1,3-dien-1-yl)phosphane;dichloropalladium;iron(2+)

Catalog No.: 
ACPLGM328
CAS No.: 
95408-45-0
Molecular Formula: 
C26H44Cl2FeP2Pd
Molecular Weight: 
651.76
ditert-butyl(cyclopenta-1,3-dien-1-yl)phosphane;dichloropalladium;iron(2+) structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g98%

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nameditert-butyl(cyclopenta-1,3-dien-1-yl)phosphane;dichloropalladium;iron(2+)
IUPAC Nameiron(II) palladium(II) bis(2-(di-tert-butylphosphaneyl)cyclopenta-2,4-dien-1-ide) dichloride
MDL No.MFCD08064219
Molecular FormulaC26H44Cl2FeP2Pd
Molecular Weight651.76
SMILES[Cl-][Pd+2]1([Cl-])[P](C(C)(C)C)(C(C)(C)C)[C-]23[CH]4=[CH]5[CH]6=[CH]2[Fe+2]56789%1043[CH]=%11[CH]%10=[CH]9[C-]8([CH]%117)[P]1(C(C)(C)C)C(C)(C)C
InChI KeyLZWLLMFYVGUUAL-UHFFFAOYSA-L
SynonymUmicore CX96
CAS No.95408-45-0

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACPLGM328 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACPLGM328 route product structure diagram
    ACPLGM32895408-45-0In Stock
Inquiry

2. ACPLGM328 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACPLGM328 route product structure diagram
    ACPLGM32895408-45-0In Stock
Inquiry

3. ACPLGM328 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACPLGM328 route product structure diagram
    ACPLGM32895408-45-0In Stock
Inquiry

Comments (0)